Immuron Limited (AU:IMC)
ASX:IMC
Top Page
Immuron Limited
(Sydney:IMC)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.03
▼(-35.00% Downside)
Action:ReiteratedDate:03/27/26
The score is driven primarily by weak financial fundamentals—ongoing losses and negative operating/free cash flow—despite some revenue growth and low leverage. Technical signals are also soft (negative MACD and price below longer-term averages), while valuation is constrained by a negative P/E and lack of dividend yield data.
Positive Factors
Low leverage
Extremely low debt-to-equity reduces financial risk and preserves capacity to fund R&D, clinical trials or commercial scale-up without meaningful interest burden. This balance sheet conservatism provides flexibility to absorb near-term revenue volatility and pursue partnerships or licensing.
Negative Factors
Negative cash flow
Sustained negative operating and free cash flow constrains the company’s ability to fund trials, COGS, and commercial expansion organically. It increases reliance on external capital raises or partnerships, which can dilute shareholders or slow programs if financing terms are adverse.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Extremely low debt-to-equity reduces financial risk and preserves capacity to fund R&D, clinical trials or commercial scale-up without meaningful interest burden. This balance sheet conservatism provides flexibility to absorb near-term revenue volatility and pursue partnerships or licensing.
Read all positive factors
Immuron Limited (IMC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$8.82M
Dividend YieldN/A
Average Volume (3M)862.36K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth48.63%
EPS Growth25.66%
CountryAU
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding326,653,600
10 Day Avg. Volume372,599
30 Day Avg. Volume862,359
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.75
Price to Sales (P/S)1.93
P/FCF Ratio-2.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$9.70M
Immuron Limited Business Overview & Revenue Model
Company Description
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Res...
How the Company Makes Money
Immuron makes money primarily through (1) product sales of its marketed oral immunotherapy, Travelan, which is sold to consumers as a prophylactic for traveler’s diarrhea via distributors/retail channels in the geographies where it is registered; ...
Immuron Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.48M | 7.29M | 4.90M | 1.80M | 765.19K | 145.78K |
| Gross Profit | 4.76M | 4.77M | 3.34M | 1.31M | 523.50K | 94.70K |
| EBITDA | -5.08M | -5.31M | -6.19M | -3.80M | -3.08M | -8.33M |
| Net Income | -4.65M | -5.22M | -6.94M | -3.79M | -2.85M | -8.38M |
Balance Sheet | ||||||
| Total Assets | 15.14M | 10.13M | 15.55M | 21.99M | 24.86M | 27.05M |
| Cash, Cash Equivalents and Short-Term Investments | 10.00M | 5.87M | 11.66M | 18.99M | 22.11M | 25.05M |
| Total Debt | 0.00 | 117.13K | 173.50K | 189.09K | 209.79K | 20.50K |
| Total Liabilities | 2.06M | 2.06M | 2.84M | 2.37M | 1.68M | 1.16M |
| Stockholders Equity | 13.08M | 8.07M | 12.71M | 19.62M | 23.18M | 25.90M |
Cash Flow | ||||||
| Free Cash Flow | -4.62M | -6.14M | -5.56M | -2.50M | -3.14M | -4.09M |
| Operating Cash Flow | -4.62M | -6.14M | -5.56M | -2.49M | -3.13M | -4.08M |
| Investing Cash Flow | -4.75K | -2.90M | 327.56K | -2.74M | 11.74K | 2.57K |
| Financing Cash Flow | 6.97M | 199.75K | 829.00 | -35.02K | -36.26K | 26.49M |
Immuron Limited Technical Analysis
Negative
0.04
Price Trends
0.03
Negative
0.04
Negative
0.06
Negative
Market Momentum
>-0.01
Positive
42.48
Neutral
20.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMC, the sentiment is Negative. The current price of 0.04 is above the 20-day moving average (MA) of 0.03, above the 50-day MA of 0.03, and below the 200-day MA of 0.06, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 42.48 is Neutral, neither overbought nor oversold. The STOCH value of 20.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IMC.
Immuron Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$33.06M | -6.66 | -370.40% | ― | 306.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$32.92M | -5.38 | -19.10% | ― | ― | -672.73% | |
44 Neutral | AU$10.20M | -0.48 | 1068.18% | ― | ― | 31.87% | |
43 Neutral | AU$8.82M | -1.29 | -43.95% | ― | 48.63% | 25.66% | |
43 Neutral | AU$17.82M | -3.69 | 2509.60% | ― | ― | -36.89% | |
40 Underperform | AU$2.84M | -1.64 | -109.45% | ― | ― | 1.03% |
* Healthcare Sector Average
AU:IMC
Immuron Limited
0.03
-0.04
-59.09%
AU:NOX
Noxopharm Ltd.
0.06
-0.01
-15.94%
AU:AVE
Avecho Biotechnology Limited
0.01
0.00
0.00%
AU:1AD
AdAlta Ltd.
―
―
―
AU:ANR
Anatara Lifesciences Ltd
0.01
>-0.01
-9.09%
AU:NSB
Neuroscientific Biopharmaceuticals Ltd.
0.10
0.06
147.50%
Immuron Limited Corporate Events
Immuron Reports Lapse of 510,107 Performance Rights
Mar 11, 2026
Immuron Limited has notified the market that 510,107 performance rights, classified as IMCAE securities, have lapsed as of March 11, 2026. The lapse occurred because the conditions attached to these performance rights were not met or became incapa...
Immuron CEO to Showcase Antibody Platform at Coffee Microcaps Conference
Mar 4, 2026
Immuron has announced that CEO Steven Lydeamore will present virtually at the Coffee Microcaps Conference on 5 March 2026, offering investors and industry participants an update on the company’s activities and product portfolio. The event hi...
Immuron Flags Strategic Reset as HY26 Results Face Audit Review
Feb 25, 2026
Immuron Limited has released a presentation outlining a strategic reset alongside its HY26 financial results, signaling a reassessment of its operational priorities and performance trajectory. The company notes that these FY2026 figures remain sub...
Immuron Narrows Half-Year Loss as Revenue Edges Higher
Feb 25, 2026
Immuron Limited reported a 4.8% increase in revenue from ordinary activities to $4.18 million for the half-year ended 31 December 2025, while its net loss after tax narrowed by 22.9% to $1.92 million, indicating improved operating performance. The...
Immuron reshapes finance and governance team with new CFO and company secretary
Feb 9, 2026
Immuron Limited has announced senior leadership changes, with long-serving Chief Financial Officer and Company Secretary Phillip Hains stepping down from both roles effective 9 February 2026. The board acknowledged his contribution since 2013, mar...
Immuron Showcases Oral Antibody Platform and GI Portfolio at Emerging Growth Conference
Jan 22, 2026
Immuron Limited announced that CEO Steven Lydeamore delivered a virtual presentation at the Emerging Growth Conference, highlighting the company’s orally delivered antibody platform and its portfolio of gastrointestinal-focused products. The...
Immuron Delivers Travelan Sales Growth and Fast-Tracks ProIBS Launch Amid North American Expansion
Jan 18, 2026
Immuron reported unaudited global first-half sales of AUD$4.2 million, up 5% year-on-year, driven primarily by strong performance of its Travelan product in Australia and the United States, despite a sharp year-on-year decline in Canada following ...
Immuron CEO to Spotlight Antibody Platform at Emerging Growth Conference
Jan 13, 2026
Immuron Limited has announced that its Chief Executive Officer, Steven Lydeamore, will deliver a virtual presentation at the Emerging Growth Conference on 22 January 2026, with the session to be made available via live webcast and archived online ...
Immuron Calls Extraordinary Meeting to Ratify Major Share Issues and Restore Capital-Raising Headroom
Jan 12, 2026
Immuron Limited has called an extraordinary general meeting of shareholders for 12 February 2026 in Melbourne to seek approval for the ratification of two substantial prior share issuances. Shareholders will be asked to ratify the issue of 28,278,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.